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Background. Pediatric Kawasaki disease (KD) and human immunodeﬁciency virus (HIV)+ adult Kawasaki-like syndrome (KLS)
are dramatic vasculitides with similar physical ﬁndings. Both syndromes include unusual arterial histopathology with immunoglob-
ulin (Ig)A+ plasma cells, and both impressively respond to pooled Ig therapy. Their distinctive presentations, histopathology, and
therapeutic response suggest a common etiology. Because blood is in immediate contact with inﬂamed arteries, we investigated
whether KD and KLS share an inﬂammatory signature in serum.
Methods. A custom multiplex enzyme-linked immunosorbent assay (ELISA) deﬁned the serum cytokine milieu in 2 adults with
KLS during acute and convalescent phases, with asymptomatic HIV+ subjects not taking antiretroviral therapy serving as controls.
We then prospectively collected serum and plasma samples from children hospitalized with KD, unrelated febrile illnesses, and non-
infectious conditions, analyzing them with a custom multiplex ELISA based on the KLS data.
Results. Patients with KLS and KD subjects shared an inﬂammatory signature including acute-phase reactants reﬂecting tumor
necrosis factor (TNF)-α biologic activity (soluble TNF receptor I/II) and endothelial/smooth muscle chemokines Ccl1 (Th2), Ccl2
(vascular inﬂammation), and Cxcl11 (plasma cell recruitment). Ccl1 was speciﬁcally elevated in KD versus febrile controls, suggest-
ing a unique relationship between Ccl1 and KD/KLS pathogenesis.
Conclusions. This study deﬁnes a KD/KLS inﬂammatory signature mirroring a dysfunctional response likely to a common eti-
ologic agent. The KD/KLS inﬂammatory signature based on elevated acute-phase reactants and speciﬁc endothelial/smooth muscle
chemokines was able to identify KD subjects versus febrile controls, and it may serve as a practicable diagnostic test for KD.
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Kawasaki disease (KD) is diagnosed based on a constellation of
ﬁndings including fever of at least 5 days plus at least 4 of the
following 5: nonexudative conjunctivitis, rash, changes of the
oropharynx, erythema and/or painful swelling of hands and
feet, and sentinel lymph node. Kawasaki disease has a predilec-
tion for coronary arteries, causing aneurysms with residual risk
for cardiovascular morbidity or mortality [1]. Intravenous im-
munoglobulin (IVIG) reduces aneurysm formation from 20%
to 4% [2, 3]. Coronary arteries in fatal KD show a mixed inﬂam-
matory pattern that includes immunoglobulin (Ig)A+ plasma
cells [4, 5]. Immunoglobulin A+ plasma cell inﬁltration occurs
in vascular and nonvascular tissues, which suggests an
infectious agent invading via respiratory tract or gut mucosa
[6]. Periodic outbreaks suggest a ubiquitous infectious etiology
[7, 8] with an atypical presentation in susceptible individuals.
Diagnosing KD is problematic because children with atypical
presentations may not receive IVIG but can develop aneurysms
and sudden death [9].
In the 1980s, an adult syndrome resembling KD, termed
Kawasaki-like syndrome (KLS), came to medical attention in
human immunodeﬁciency virus (HIV)+ adults with advanced
disease [10]. Patients with KLS are treated with IVIG like KD
patients, and they have similar responses (see reviews in John-
son et al [11] and Stankovic et al [12]). In a setting of limited
evaluations, no aneurysms have been documented in KLS; how-
ever, aneurysms occur in HIV-seronegative adults with KD [13,
14]. In 2003, a KLS conjunctival biopsy showed IgA+ plasma
cells inﬁltrating arterial walls, linking KLS to KD by histopa-
thology. The same study showed elevated soluble tumor necro-
sis factor receptor (sTNFR)II levels, suggesting a role for TNF-α
in pathophysiology [15].
Understanding pathophysiology may improve KD/KLS diag-
nosis and treatment. Inﬂammatory responses can be catego-
rized by cytokine patterns of activated CD4 T cells. In broad
terms, responses to intracellular pathogens (eg, viruses) feature
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interferon gamma ([IFN-γ] labeled Th1) to (1) parasites and al-
lergens interleukin (IL)-4 and IL-13 (Th2) and to (2) some bac-
terial infections and autoimmune diseases IL-17 (Th17)
(reviewed in [16]). Chemokines recruit speciﬁc cell types to in-
ﬂamed tissues, they are cell lineage speciﬁc, and they are differ-
entially regulated in Th1/Th2 cytokine milieus (reviewed in
[17]). We used this immunobiology as the framework to design
(1) a multiplex ELISA investigation of cytokine milieu in 2 KLS
cases and (2) a subsequent KD investigation that allowed us to
compare the KD and KLS inﬂammatory signatures.
Case 1
Patient 1 is 23-year-old male with fevers, rash, strawberry
tongue, painful swelling of hands and feet, and nonexudative
conjunctivitis, preceded by diarrhea and abdominal pain (Fig-
ure 1). Admission evaluation revealed HIV/acquired immune
deﬁciency syndrome (CD4 = 3; viral load 180 000 copies/mL).
On hospital day 9, the patient had persistent fevers (103.9°F),
and developed severe hypotension (maximum ﬂuid resuscita-
tion and pressors) in spite of empiric antimicrobials plus hydro-
cortisone; the workup for infectious etiologies was entirely
negative (Supplementary Table 1). In the intensive care unit,
he was diagnosed with KLS and treated with IVIG without as-
pirin due to thrombocytopenia, with a rapid response including
fever resolution and pressor discontinuation within 24 hours.
Without deterioration, fevers relapsed 4 days after IVIG no. 1,
which led to a second infusion (IVIG no. 2). The relapsed fever
only resolved with subsequent initiation of aspirin therapy en-
abled by improved platelet counts. With permission from the
patient, serum was collected before IVIG no. 1 and 13 weeks
postdischarge.
Case 2
Patient 2 is a 31-year-old HIV+ male (CD4 = 19, viral load
139 000 copies/mL) with idiopathic eosinophilia who presented
with 10 days of fever (102.7°F), myalgia, mild abdominal pain
and diarrhea, painful swollen hands and feet. Findings included
nonexudative conjunctivitis, cracked lips, mild thrush, cervical
lymphadenopathy, impressive painful swelling of hands and
feet, and rash. On hospital day 5, the patient remained febrile
(103°F) but testing was negative (Supplementary Table 1). He
was treated with IVIG and aspirin, defervesced during the infu-
sion, and felt remarkably better. He was discharged the follow-
ing day on previously prescribed antiretroviral medication plus
aspirin. He returned to clinic at 2 and 5 weeks, and he appeared
well on both visits. With permission serum was collected before
IVIG and 5 weeks postdischarge.
Both patients had desquamation involving the hands at ap-
proximately 2 weeks, as typically seen in KD. Neither patient
had a recurrence in the following 5 years; detailed clinical sum-
maries are included in the Supplementary Data.
METHODS
Kawasaki-Like Syndrome Investigation
A case-control study was performed with approval from the In-
diana University Institutional Review Board (IRB). A custom
multiplex ELISA with analytes representing cytokine polariza-
tion, tissue/cell-type speciﬁc inﬂammation, and/or KD/KLS as-
sociation was designed (Supplementary Table 2). Analyte levels
in acute and convalescent KLS serum were compared with levels
in asymptomatic HIV+ male serum (CD4 > 350 not taking com-
bination antiretroviral therapy) leftover from an unrelated study
[18]. Serum from a healthy female was included to preliminarily
identify analytes abnormally low in HIV+ individuals. A com-
mercial laboratory routinely servicing large clinical trials ([19,
20]) (Aushon Biosystems, Woburn, MA) performed multiplex
ELISA on blinded samples. Samples 1 and 2 comprised acute/
convalescent sera from patient 1; samples 3 and 4 comprised
acute/convalescent sera from patient 2; samples 5–7 comprised
Figure 1. Physical findings in patient no. 1. Sequential panels showing rash,
changes of the oropharynx, nonexudative conjunctivitis, and erythema with mild
swelling of hands.
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HIV controls; and sample 8 comprised a seronegative female
(dataset in Supplementary Table 3). An in-house ELISA was
performed to quantify IFN-γ (human IFN-γ ELISA kit;
Pierce-Endogen, Rockford, IL).
Kawasaki Disease Study
Based on our KLS investigation, we hypothesized that IL-6, IL-
13, and sTNFRI/II along with chemokines Ccl1, Ccl2, and
Cxcl11 would be elevated in KD and that elevated sTNFRI/II
plus Ccl1, Ccl2, and Cxcl11 would selectively identify KD cases.
A custom multiplex ELISA was designed for the KD study in-
cluding IL-1β (anticipated negative acute-phase reactant), IL-4
(Th2), IL-13 (Th2), Ccl1 (Th2 chemokine), Ccl2 (vascular in-
ﬂammation), Ccl11 (Th2 chemokine), Ccl4 (anticipated nega-
tive Th1 chemokine), Cxcl9 (neutrophil recruitment), and
Cxcl11 ( plasma cell recruitment). In the context of a small
study, paired serum and plasma samples (pseudo-duplicates)
were obtained to address outliers and determine optimal sam-
ple type. Blood sampling was done before IVIG for KD
subjects.
The prospective KD study was performed between Septem-
ber 2014 and July 2015. Children >6 months and <8 years
were enrolled into 3 groups: (1) KD, (2) febrile illness (febrile
controls [FC]), and (3) noninfectious illness (healthy controls
[HC]). Inclusion criteria included formal KD diagnosis (KD),
fever >38.2°C during evaluation, a non-KD working diagnosis
without rash (FC), and admission for noninfectious condition
(HC). Exclusion criteria included known HIV+ status or genetic
disorder (all) and absence of a working diagnosis or presence of
rash (FC). Serum and plasma datasets are in Supplementary Ta-
bles 5 and 6. The IRBs at Indiana University Riley Children’s
Hospital and Children’s Hospitals and Clinics of Minnesota ap-
proved this study.
Statistical Analysis
For KLS, data were analyzed as individual comparisons of pa-
tient 1 and 2 acute and convalescent values to the combined an-
alyte data from 3 HIV+ control subjects with a Student’s t test.
“Normal serum” was not included in analyses. For within-study
comparisons, P values of <.05 were considered signiﬁcant.
Power analyses to guide follow-up studies were performed,
and these results are included in the legend of Figure 3.
Based on our KLS data and the literature [15, 21], we postu-
lated that KD would be inextricably linked to a marked eleva-
tion in sTNFRI/II or IL-6 and that elevations in Ccl1, Ccl2, and
w Cxcl11 would identify KD versus FC. Elevations in sTNFRIl/
II were conﬁrmed during preliminary examination of data.
One-way analysis of variance with Tukey post hoc tests and re-
ceiver operator curve (ROC) analyses were performed on
sTNFRI/II and IL-6 to determine optimal cutoffs. An sTNFRII
cutoff of >1900 pg/mL eliminated all HC and 3 FC, step 1 of a 2-
step algorithm. We then performed t tests with Welch correc-
tion and ROC analyses on subjects with sTNFRII levels
>1900 pg/mL to determine whether remaining analytes were
uniquely elevated in KD versus FC. For pathogenesis-speciﬁc
chemokines Ccl1 (P value = .036), Ccl2 (P value = .024), and
Cxcl11 (P value = .13) identiﬁed in our KLS study as possible
“KD predictors”, a ROC analysis was performed to ﬁnd optimal
cutoffs; Ccl1 (>3.55 pg/mL), Ccl2 (>715 pg/mL), and Cxcl11
(>39.4 pg/mL). Educated by samples 12 (KD) and 26 (FC)
with similar measurements (Table 1), we found that at least 2
KD predictors were needed to appropriately identify these
subjects; a comprehensive statistical analysis description is in
Supplementary Data.
RESULTS
Kawasaki-Like Syndrome Study
Kawasaki-like syndrome results can be grouped into 3 categories.
In the ﬁrst category, analytes not elevated in KLS were compared
with HIV+ controls. This category includes IL-17 and Ccl5 (Sup-
plementary Figure 1) and IL-1β (below limit of detection).
The second category includes analytes related to KLS severity.
Of these, IFN-γ, Cxcl10, osteoprotegerin, TNF-α, IL-1ra, and
IL-10 were elevated only in patient 1 with shock (Figure 2). Al-
though the results were statistically signiﬁcant, Cxcl10 is includ-
ed in this category because the level in patient 2 was only 30%
higher than HIV+ controls; IL-1ra was included here because
the “elevated” level in patient 2 was lower than the level
found in normal serum. Macrophage colony-stimulating factor
was elevated in typical KLS and persistently elevated in severe
KLS. Interferon-α (Figure 2, top right panel) was elevated in
typical KLS and absent in KLS shock (KLSS). Although conclu-
sions cannot be drawn based on 2 patients, an inadequate IFN-
α response may be a marker for severe disease.
The third (interesting) category includes analytes elevated in
acute KLS that, during the convalescent phase, decreased to or
toward levels seen in HIV+ controls. The category includes IL-6,
sTNFRII, IL-13, Ccl1, Ccl2, and Cxcl11 (Figure 3). As previously
reported in KD [22, 23], IL-6 and Ccl2 were elevated in KLS. As
previously reported in KLS [15], sTNFRII was markedly elevat-
ed in both KLS patients. Particularly interesting were elevations
in IL-13 (Th2), and chemokines Ccl1 (Th2), and Cxcl11, a plau-
sible link to pathognomonic IgA+ plasma cell inﬁltration of ar-
terial walls in KD/KLS. Supplementary Table 4 summarizes the
KLS results versus published data for KD and non-KD illnesses.
Kawasaki Disease Study Results
Sixteen KD, 13 FC, and 10 HC subjects were enrolled. Two FC
were excluded before analysis: subject-2101 was 9 years old (too
old), and subject-2102 had a prominent rash of unknown etiol-
ogy (a predeﬁned exclusion criterion). Sixteen KD (1 with an-
eurysms, 1 incomplete, 1 IVIG-resistant), 11 FC, and 10 HC
were included in the ﬁnal analyses; demographics and clinical
ﬁndings are in Supplementary Tables 7–9.
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Multiplex ELISA testing (Figure 4) showed that KD univer-
sally included marked elevations in acute-phase reactants IL-6
or TNF-α surrogates TNFRI/II but usually in both. There
were signiﬁcant differences or trends in KD versus FC in
KLS-implicated pathogenesis-chemokines Ccl1, Ccl2, and
Cxcl11. Cxcl11 did not reach signiﬁcance (P = .13) due to a
high level (3488 pg/mL) in KD subject-1101. Subject-1101
was arguably the sickest subject with an echocardiography left
anterior descending z-score of +2.69, marked perivascular
brightness around the coronaries, and the highest C-reactive
protein (CRP) in the study at 34.4 mg/dL (see Supplementary
Table 8). The markedly elevated Cxcl11 may have reﬂected
the severity of the vasculitis. The high Cxcl11 level for sub-
ject-1101 did not appear to be erroneous because it was similar-
ly elevated in paired-plasma (pseudo-duplicate as per study
design). The KD Cxcl11 mean without subject-1101 was 163
Figure 2. Analytes reflecting severity of Kawasaki-like syndrome (KLS). Patient 1 (severe KLS shock), black squares; patient 2 (typical KLS), gray circles. The control human
immunodeficiency virus (HIV) subjects’ mean (open square) and range of analyte values are indicated in the third column. The level of analyte in a single HIV-negative “normal
serum” is shown as a square in the final column. For interleukin (IL)-1ra, note (1) the break in the scale and (2) that the level of IL-1ra in HIV-negative normal serum is higher than
in HIV+ control subjects. Interferon (IFN)-γ and tumor necrosis factor (TNF)-α for the HIV+ controls and normal serum were below the limit of detection and were plotted as “0”.
*P value <.05; **P value <.01. OPG, osteoprotegrin.
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pg/mL. With subject-1101 absent, the Cxcl11 P value based on
15 KD subjects was .008. The acute-phase reactant IL-1β and
the Th1 chemokine Ccl4 were not speciﬁcally elevated in KD
nor was the Th2 chemokine Ccl11. Elevated IL-13 documented
in KLS was not seen in KD nor was previously reported eleva-
tion in Th2 cytokine IL-4. Cxcl9 was elevated in KD, but ROC
analysis showed that Cxcl9 did not separate KD from FC. Before
the KD study, we hypothesized that elevated sTNFRI/II com-
bined with elevated pathogenesis-chemokines Ccl1, Ccl2, and
Cxcl11 would be a diagnostic test for KD. Based on that hypoth-
esis, we tested a 2-step algorithm. Using a TNFRII level of
>1900 pg/mL as the cutoff for considering a KD diagnosis, sec-
ondary ROC analysis showed that elevations in 2 or more path-
ogenesis-chemokines (Ccl1, Ccl2, Cxcl11) accurately identiﬁed
all KD versus FC (Figure 5; Table 1).
DISCUSSION
Our investigation shows that KD and KLS share an inﬂamma-
tory signature including a robust acute-phase response
(sTNFRI/II) and elevations in pathogenesis-speciﬁc chemo-
kines Ccl1, Ccl2, and likely Cxcl11. We posit that KD and KLS
are the same disease based on inﬂammatory signatures, com-
bined with unusual arterial histopathology (IgA+ plasma
cells), similar physical ﬁndings, and rapid clinical responses to
IVIG. The KD/KLS inﬂammatory signature is compatible with
an infectious agent, perhaps the ribonucleic acid (RNA) virus-
like particles visualized in pathology specimens using reverse-
engineered KD IgA antibodies [24, 25].
This is the ﬁrst reported case of KLSS. It manifested similar to
KD shock syndrome ([26–28]). The mechanism appears to be a
cytokine storm with high TNF-α and IL-6 and an ineffective
Figure 3. Analytes elevated in Kawasaki-like syndrome (KLS) patients in the acute phase that, during the convalescent phase, return to or toward levels seen in asymp-
tomatic human immunodeficiency virus (HIV)+ control subjects. Patient 1 (severe KLS), black squares; patient 2 (typical KLS), gray circles. For chemokines, the common no-
menclature is used on the y-axis; the graph body is labeled with the systematic name. Power analyses of these pilot data suggest a confirmatory sample size as small as 3
controls and 3 cases for interleukin (IL)-6, tumor necrosis factor receptor (TNFRII), Ccl1, Ccl2, and Cxcl11; 6 controls and 3 cases for IL-13. *P value <.05; **P value <.01.
Abbreviations: MCP, monocyte chemoattractant protein; sTNFRII, soluble TNFRII.
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counter-inﬂammatory response (IL-10/IL-1ra). This case dem-
onstrates that KLS is potentially fatal and that IVIG should be
administered beyond the 10-day febrile cutoff used in
pediatrics.
Our investigation of 2 KLS patients at clinical extremes sug-
gests that IFN-α is important for host protection in KD/KLS.
The typical KLS patient (Case 2) had elevated IFN-α (46 ρg/
mL) with undetectable IFN-γ; the KLSS patient had elevated
IFN-γ (27 ρg/mL) with undetectable IFN-α, a starkly inverted
pattern. For comparison, IFN-γ serum levels during viral ill-
nesses run 8–30 ρg/mL [29–31]; IFN-α levels in children with
inﬂuenza had a mean of 602 ρg/mL [32]. Kawasaki disease in-
vestigators have documented low to undetectable serum IFN-α
levels [33–35]; however, the KD coronary artery transcriptome
shows a prominent type I IFN molecular ﬁngerprint; ie, evi-
dence for local IFN activity during KD arteritis [36]. If KD
Figure 4. Results of Kawasaki disease (KD) study. Top row shows acute-phase reactants: soluble tumor necrosis factor receptors (sTNFR) and interleukin (IL)-6. Row 2 illustrates
pathogenesis-specific chemokines. Rows 3 and 4 show analytes related to polarization of the immune response. For chemokines only, common nomenclature is used on the y-axis
and the graph body is labeled with the systematic name. Note that data are plotted on log scale. *P value <.05; **P value < .01; ****P value < .0001. Abbreviations: ITAC,
interferon-inducible T-cell chemokine; MCP, monocyte chemoattractant protein; MIG, monocyte interferon-γ-inducible protein; MIP, macrophage inflammatory protein.
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susceptibility is determined by suboptimal innate IFN-α re-
sponses, then low IFN-α levels do not argue against its role in
protection or against an RNA virus-like etiologic agent.
Our KD results are consistent with published data. We found
Cxcl9 elevated in KD, consistent with a recent serum study [37]
and the coronary artery transcriptome [36]. Soluble TNFRI/II
(TNF-α activity) within the inﬂammatory signature has been
individually reported by others [15, 21] and seems to play a cen-
tral role in pathogenesis. The mechanism-speciﬁc chemokines
Ccl2, Cxcl11, and Ccl1 investigated in this study are the unique
aspect of the KD/KLS inﬂammatory signature.
Ccl2 (endothelial/smooth muscle cells) is a biomarker for
myocardial infarction risk [38] and was previously shown to
be elevated in KD [39, 40]. In this study, we identify Cxcl11 as
a likely new KD-associated chemokine (unadjusted P value of
.13; adjusted P value of .008). Its receptor Cxcr3 is present
and functional on human IgA+ plasma cells [41], consistent
with recruitment into arterial walls. Elevated Cxcl11 is associat-
ed with human aortic aneurysms, and Cxcr3 is required for an-
eurysm formation in mice [42]. Engagement of Cxcr3 by Cxcl9,
Cxcl10, and Cxcl11 results in its removal from the cell surface.
Children with KD have reduced Cxcr3 on circulating T cells at-
tributed to Cxcl10 [43]; Cxcl11 is a more potent Cxcr3
Figure 5. Two-step Kawasaki disease (KD) diagnostic algorithm. Abbreviation:
sTNFR, soluble tumor necrosis factor receptor.
Table 1. Testing the Kawasaki Disease Algorithm
pg/mL
Test ID hITAC hMCP1 hI309 ITAC > 39.4 MCP1 > 715 I309 > 3.55 Algorithm Classificationa
Sample 2 131.2 1156.1 Low sample volume TRUE TRUE TRUE KD
Sample 4 565.2 11140.2 22 TRUE TRUE TRUE KD
Sample 6 61 1201.8 16.4 TRUE TRUE TRUE KD
Sample 8 39.5 1837 9.7 TRUE TRUE TRUE KD
Sample 10 162.3 804.6 11.5 TRUE TRUE TRUE KD
Sample 12 29.3 752 3.8 FALSE TRUE TRUE KD
Sample 14 67.2 2878.9 169.9 TRUE TRUE TRUE KD
Sample 16 68.9 983.5 36.9 TRUE TRUE TRUE KD
Sample 18 40.7 574.3 15 TRUE FALSE TRUE KD
Sample 60 3487.8 3285.9 47.1 TRUE TRUE TRUE KD
Sample 62 191.4 1360.7 9.7 TRUE TRUE TRUE KD
Sample 64 134.7 1393.6 4 TRUE TRUE TRUE KD
Sample 66 108.7 1624 13.8 TRUE TRUE TRUE KD
Sample 68 257.1 1458.7 21.9 TRUE TRUE TRUE KD
Sample 70 484.9 2189.8 22.6 TRUE TRUE TRUE KD
Sample 72 109.6 1366.2 18.1 TRUE TRUE TRUE KD
Sample 24 14 650.8 4.1 FALSE FALSE TRUE not KD
Sample 26 16 792.3 2.6 FALSE TRUE FALSE not KD
Sample 28 33.7 266.4 3.1 FALSE FALSE FALSE not KD
Sample 30 25 399.7 4.9 FALSE FALSE TRUE not KD
Sample 34 15.9 677.5 3.5 FALSE FALSE FALSE not KD
Sample 36 39.3 499.7 4.2 FALSE FALSE TRUE not KD
Sample 38 11.3 506.1 3.6 FALSE FALSE TRUE not KD
Sample 78 109.7 586.1 3.3 TRUE FALSE FALSE not KD
Samples highlighted in light gray are KD subjects; samples highlighted in red are FC subjects with sTNFRII values >1900 pg/mL.
Abbreviations: I309, inflammatory cytokine 309; ITAC, interferon-inducible T-cell chemokine; MCP, monocyte chemoattractant protein; KD, Kawasaki Disease.
a>2 true equals a diagnosis of KD.
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internalization trigger than Cxcl10 [44–46]. Cxcr3 inhibitors,
potentially KD therapeutics, have entered clinical trials for
other purposes [47, 48].
Ccl1 was uniquely elevated in KD in this 39-subject study.
Ccl1 is produced by human endothelial cells exposed to athero-
genic apolipoprotein A. The Ccl1 receptor Ccr8 is found on Th2
cells [49]; however, Ccr8 is also expressed by human vascular
smooth muscle cells. In a mouse model, femoral artery luminal
trauma induced Ccl1 production by smooth muscle cells, sug-
gesting that Ccl1/Ccr8 is involved in vascular injury repair
[50]. Ccl1 seems to be intimately and uniquely tied to KD/
KLS-triggered vascular injury.
The Th1/Th2/Th17 polarization paradigm has been used to
interpret KD pathogenesis. Interferon-γ, the prototype Th1 cy-
tokine, is not typically elevated in KD [35, 51]; children with el-
evated IFN-γ are at higher risk of aneurysms [34]. In this report,
the adult HIV+ patient with detectable IFN-γ went into shock.
In contrast, IL-4, the prototypic Th2 cytokine, has previously
been reported elevated in children with KD [35], and the Th2
chemokine Ccl17 recently shown elevated in KD [37]. Idiopath-
ic eosinophilia (Th2 phenomenon) is seen in KD [52–54] and in
non-HIV adult KD [14]. KLS patient 2 with typical KLS had id-
iopathic eosinophilia, a recognized condition in advanced HIV
disease [55, 56].We investigated the Th2 chemokine Ccl11 (reg-
ulated by IL-4), which was not elevated. The Th1 chemokines
elevated in KD (Cxcl9, Cxcl10, Cxc11, Ccl2) would recruit Th1
cells as available, but those chemokine levels are regulated by
IFNs (including IFN-α) and/or TNF-α unrelated to cytokine
polarization. We investigated Th1 chemokine Ccl4 produced
by activated cells of several types, which was not elevated. We
found that IL-13, a quintessential Th2 cytokine, was elevated
in both KLS patients. The IL-13 levels in KD children were
low, and differences between KD and FC were not signiﬁcant,
perhaps reﬂecting the difference between reactivation/recall in
KLS versus a primary response in KD. We and others [57–59]
have shown that CD8 T cells produce IL-13. CD8 T cells pre-
dominate in acutely inﬂamed KD coronary arteries [60]. It is
unclear whether the CD4-based Th1/Th2/Th17 paradigm is a
good ﬁt for KD/KLS pathogenesis.
Our results suggest a KD/KLS diagnostic test based on
elevated sTNFRI/II combined with elevations in pathogenesis-
speciﬁc chemokines Ccl1, Ccl2, and Cxcl11. A previously
published KD diagnostic algorithm based on 12 conventional
laboratory parameters (CRP, total white blood cell count, etc)
had a sensitivity of 74.3% and a false-positive KD diagnosis
rate of 37.2% for FC [61].An improved version of this algorithm
was published during the revision process for this manuscript
[62]. Kawasaki disease pathophysiology has been investigated
using advanced transcriptomics, proteomics, and multiplex
ELISA. Urine proteomics identiﬁed KD biomarkers including
meprin A [63], and peripheral blood mononuclear cells
(PBMCs) transcriptomics identiﬁed KD transcripts, including
130 differing between KD and adenovirus-infected children
[64–66]. The analytes in our inﬂammatory signature are not
among the 130 transcripts. It is not clear whether urine protein
or circulating PBMC mRNA optimally reﬂect vascular wall in-
ﬂammation. Ko et al [43] recently used commercial multiplex
ELISA arrays to investigate KD versus FC and demonstrated
that Cxcl10 was differentially elevated in KD. Our custom 12-
plex KD ELISA contained 3 analytes investigated in that study
with the same results: there was no difference in IL-1β and in-
signiﬁcant trends toward elevated IL-4 and IL-6 in KD versus
FC.
CONCLUSIONS
Kawasaki disease and KLS are likely the same disease, based on
a shared inﬂammatory signature. Speciﬁc signature compo-
nents, elevations in sTNFRII, and at least 2 of 3 pathogenesis-
associated chemokines (Ccl1, Ccl2, and Cxcl11), were able to
identify KD subjects versus FC and healthy children as diag-
nosed by experienced clinicians at 2 major pediatric tertiary re-
ferral hospitals. This was not a deﬁnitive study of the KD
inﬂammatory signature’s utility in general practice. Children
with febrile illness and rash were speciﬁcally excluded because
incomplete KD is a difﬁcult diagnosis, with existing diagnostic
criteria based solely on expert opinion [67]. Inclusion of febrile
illnesses with rash as controls (eg, viral syndrome) in this initial
investigation would have required study-dictated diagnostic
viral testing and echocardiography to ensure that cases of in-
complete KD did not get assigned to the febrile control
group. Follow-up studies will include controls with deﬁned fe-
brile rashes (eg, adenoviral infections), and an investigation to
determine whether KD diagnoses can be made as early as day 3
of fever in the setting of at least 1 of the following: nonexudative
conjunctivitis, rash, painful swelling, or erythema of hands or
feet. Results of this study also suggest that investigations of
type 1 IFNs, Cxcl11/Cxcr3, and Ccl1/Ccr8 will provide new in-
sights into KD and KLS pathogenesis.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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